Search Products

iPSC Gene Editing

Induced pluripotent stem cells (iPSCs) are pluripotent stem cells that, in theory, can be differentiated into any cell type or tissue. The combination of iPSCs with gene editing technologies offers vast potential for applications in areas such as disease modeling, drug screening, personalized cell therapies, and regenerative medicine.

Service Details

Services Gene Knockout iPS Cells/Gene Point Mutation iPS Cells/Gene Overexpression iPS Cells/Gene Interference iPS Cells/CRISPR Library Screening Related to iPS Cells
Turnaround/Price   Consult online for details
EDITGENE has years of experience in stem cell culture and a well-established gene editing platform, enabling efficient gene editing for iPS cells. We emphasize the importance of maintaining an optimized iPS cell culture system to prevent differentiation during the editing process. Based on client requirements, we can construct a wide range of gene-edited iPS cell models, including gene knockouts, point mutations, knock-ins, overexpression, and gene interference.

iPSC In Vitro Disease Modeling Research Pathway

 Gene-Edited iPS Cell Models

Can be induced to differentiate into large quantities of target cell types, serving as substitutes for primary cells in personalized cell therapy and drug screening.
  Can create human-derived cell models or organoids that realistically simulate disease processes, avoiding animal experiments and preventing inaccurate results.

Service Types

Gene editing solutions and iPS cell line construction can be customized according to client requirements and specific gene considerations:
1 Gene Knockout iPS Cells
2 Gene Point Mutation iPS Cells
3 Gene Knock-in iPS Cells
4 Gene Overexpression iPS Cells
5 CRISPR Library Screening for iPS Cells

EDI-Service Advantages

Extensive Experience in Stem Cell Cultivation
Ensuring the pluripotency of iPS cells.
Advanced Gene Editing Platform

Designing target gene editing iPS cell models based on experimental needs.

Workflow

Advantage and Characteristic

Optimazied Strategy
We have create a unique sgRNA Design Logic
Optimazied Strategy
We have create a unique sgRNA Design Logic
Optimazied Strategy
We have create a unique sgRNA Design Logic
Optimazied Strategy
We have create a unique sgRNA Design Logic

Genetic Reference Book

Four key factors, Oct4, Sox2, Klf4, and c-Myc, can induce cell reprogramming into iPSCs
Article Title: Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors

This article discusses the technology of converting mature fibroblasts into pluripotent stem cells through specific transcription factors. The study utilized four key transcription factors—Oct4, Sox2, Klf4, and c-Myc—introduced into mouse embryonic and adult fibroblasts. Through the action of these factors, the cells gradually acquired pluripotent characteristics, exhibiting morphology and gene expression patterns similar to embryonic stem cells. The study found that the reprogrammed iPSCs could not only be maintained long-term in vitro but also differentiate into various cell types, including neural cells and cardiomyocytes, indicating that these iPSCs have favorable biological characteristics and potential applications. This study validates the effectiveness of these four transcription factors and provides new tools for future stem cell research, especially in regenerative medicine and disease treatment.

Article Title: iPSC-derived lung and lung cancer organoid model to evaluate cisplatin encapsulated autologous iPSC-derived mesenchymal stromal cell-isolated extracellular vesicles

Lung cancer remains the leading cause of cancer-related mortality worldwide. Despite advancements in targeted therapies, drug resistance and systemic toxicity are persistent issues. This study investigates the feasibility of using patient-specific lung cancer and normal lung tissue organoid models, as well as autologous induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cell (MSC)-isolated extracellular vesicles (EVs) in personalized medicine. Healthy fibroblasts were reprogrammed into iPSCs, which differentiated into branching lung organoids (BLO) and patient-matched lung cancer organoids (LCO). EVs were isolated from iPSC-MSCs and loaded with 0.07 µg/mL cisplatin, applied to both organoid models, and cytotoxicity was recorded through LDH and CCK8 assays. The results showed that fibroblast-derived iPSCs exhibited a normal karyotype and pluripotency, while iPSC-derived BLOs and LCOs expressed lung markers. Cisplatin-loaded iPSC-MSC-derived EVs caused no cytotoxicity in either organoid model, whereas 20 µg/mL cisplatin was cytotoxic to LCOs. This study presents an initial validation method for using autologous or allogeneic iPSC-MSC EVs as a testing platform for lung cancer drug delivery.

Article Title: Macrophages derived from human induced pluripotent stem cells (iPSCs) serve as a high-fidelity cellular model for investigating HIV-1, dengue, and influenza viruses

This study assesses whether human iPSC-derived macrophages serve as effective models for studying viral biology. The findings show that these iPSC-derived macrophages support the replication of HIV-1, dengue, and influenza viruses, with replication dynamics and phenotypes comparable to traditional blood monocyte-derived macrophages. Flow cytometry, RNA sequencing, and chromatin accessibility analyses showed that iPSC-derived macrophages closely resemble human blood monocyte-derived macrophages in surface markers and gene expression characteristics. Additionally, iPSC lines generated from chimpanzee fibroblasts exhibited different susceptibilities to dengue virus, providing a valuable resource for studying viral host tropism. The study also found that both blood-derived and iPSC-derived macrophages could restrict viral replication in the late stage of the influenza virus lifecycle. Overall, iPSC-derived macrophages have proven to be a suitable alternative to blood monocyte-derived macrophages for studying viral biology.

FAQ

What is the difference between iPSCs and embryonic stem cells (ESCs)?
Both iPSCs and embryonic stem cells (ESCs) are pluripotent, but iPSCs are derived from reprogrammed somatic cells, while ESCs originate from early embryos. iPSCs do not involve embryo use, making them a more ethically acceptable choice, and they also avoid immune rejection issues, as they can be generated based on a patient’s genetic background.
Cells from patients are isolated and reprogrammed into iPSCs, which are then induced to differentiate into specific cell types to create disease models. These models enable researchers to study disease mechanisms, uncover disease-related genes, and molecular pathways, thereby advancing the development of new therapies. By analyzing these cells, scientists can observe disease-related changes at the cellular level, providing new perspectives in disease research.
iPSCs have broad clinical potential, including applications in cell therapy (e.g., for diabetes or heart disease treatment), tissue engineering (e.g., development of artificial skin or liver tissue), and personalized drug screening (e.g., selecting optimal treatments based on a patient’s specific cellular response). These applications may transform treatment methods, offering more effective and personalized medical services.
Induced pluripotent stem cells (iPSCs) are cells reprogrammed from adult cells to a pluripotent state. They exhibit similar characteristics to embryonic stem cells, capable of differentiating into nearly all cell types in the body. This technology allows scientists to generate various cell types in vitro for research and therapy without the need for embryonic stem cells.
EDGENE
Contact US
web logo
Kathy
Email: info@editxor.com
Tel: +1 224345 1927 (USA)
Tel: 833 2263234(USA ToIl-free)
Tel: +86 19120102676 (Intl)
✖ service online
✖